Immunome, Inc.

Immunome, Inc. is a biotechnology company focused on developing antibody-based therapeutics by unlocking the human memory B cell response. Founded in 2008 and headquartered in the United States, the company has a growing pipeline of cancer immunotherapies fueled by the human immune system. Immunome's proprietary technology platform leverages the "most highly educated" immune systems from patients to simultaneously discover novel antigens and patient-derived native antibodies. This unique approach enables the identification of specific and high-affinity antibodies with significant therapeutic potential to revolutionize cancer treatment. The company recently received a notable $230.00M Post-IPO Equity investment on 13 February 2024. With its innovative approach and promising pipeline, Immunome is poised to make a substantial impact in the Biopharma, Biotechnology, and Pharmaceutical industries.